Healthcare-focused lower middle market private equity firm
NaviMed Capital
- HeadquartersRosslyn, VA S1
- Websitenavimed.com
- Last verifiedNovember 6, 2026
At a glance
| Latest fund | NaviMed Fund III, $450M (Nov 2024) S4 |
|---|---|
| EBITDA range | Up to $10M S2 |
| Revenue range | $10M to $100M S2 |
| Check size | $5M to $30M S2 |
| Deal types | Platform, Add-on, Minority, Growth S2 |
| Geography | North America S2 |
| Sectors | Healthcare Services |
What NaviMed Capital buys
NaviMed Capital is a healthcare-only private equity firm based in Rosslyn, Virginia, just outside Washington, DC. It backs fast-growing lower middle market companies in healthcare services, healthcare IT, hospital products and distribution, and its newest deals lean toward outsourced services. For a new platform it wants $10 million to $100 million of revenue, up to $10 million of EBITDA and double-digit growth. It puts in $5 million to $30 million of equity, and says it can go well above that, for either control or a substantial minority stake.
The firm closed Fund III at its $450 million hard cap in November 2024, up from $290 million for Fund II. Its usual deals are family succession sales, founder recapitalizations, management buyouts, corporate carve-outs and roll-ups led by senior executives. A smaller company can still fit as an add-on: that takes just over $1 million of revenue, with no EBITDA minimum. Companies need to be in North America.
Recent deals
Announced in the 24 months before November 6, 2026.
| Date | Company | Type | Sector | Source |
|---|---|---|---|---|
| Jun 2026 | Metrix and Versado CommunicationGrowth investment behind the combination of two life sciences training firms, Metrix of Toronto and Versado of Raleigh; stake not disclosed | Growth | Source | |
| 2025 | VitoriaPharmacy services for long-term care patients, based in Garland, Texas | Investment | Healthcare Services | Source |
| 2025 | TILTBrand strategy and marketing for hospitals and health systems, based in Birmingham, Michigan | Investment | Source | |
| 2025 | InfusiveSoftware-enabled supply chain and inventory services for retail health clinics and compounding pharmacies, based in Charlotte | Investment | Source | |
| Nov 2024 | NaviMed Fund IIIClosed at its $450 million hard cap | Fund close | Source |
Portfolio by sector
From the firm's portfolio page S3.
Outsourced Services
- Infusive
- Metrix
- TILT
Payors / Payments
- OPN Healthcare
Products / Outsourced Pharma
- CiTRUS Health
- ClariMed
Specialty Services / Behavioral Care
- BrentCare
Specialty Services / Post-Acute and Long-Term Care
- Advantage Surgical
- Neulife
- Vitoria
Past investments: EnableComp (formerly Argos Health), Lighthouse Lab Services, Lucent Health, Centerpointe Hospital, The CM Group, Velocity Clinical Research
Greymont’s take
How NaviMed Capital fits a seller
NaviMed suits a healthcare owner who wants a specialist investor and is ready to grow, including by buying other companies. Because it will take a substantial minority as well as control, an owner who wants to keep the majority can still have the conversation. Family succession and founder recapitalizations are on its list of usual deals, and it brings in seasoned executives: Metrix and Versado gained a former portfolio company CEO as executive chairman.
It shows EnableComp and Lighthouse Lab Services as partly exited after sales to Welsh Carson and Martis Capital, so a sale to a larger investor can be a step and not the end of its involvement. An owner should ask exactly what stake NaviMed wants, since the Metrix deal was called a growth investment with no stake disclosed. If you keep equity, also ask how long it expects to hold and how a later sale would work.
Questions owners ask
What stake does NaviMed Capital take?
Its criteria cover both control and substantial minority investments, with $5 million to $30 million of equity and room to invest more. The June 2026 Metrix and Versado announcement calls its money a growth investment and does not say what stake it holds.
How small a company will NaviMed Capital look at?
A new platform should have $10 million to $100 million of revenue and up to $10 million of EBITDA. For an add-on to a company it already owns, it asks for more than $1 million of revenue and sets no EBITDA minimum.
How much capital does NaviMed Capital have to invest?
Its news page reports that Fund III closed at a $450 million hard cap on November 20, 2024, up from $290 million for Fund II in April 2021. Its portfolio page shows four new investments dated 2025 and 2026.
Does NaviMed Capital invest outside the United States?
Its criteria call for North American companies, and that reaches into Canada. Metrix, which it backed in the June 2026 combination with Versado of Raleigh, North Carolina, is headquartered in Toronto.
Sources
- S1NaviMed Capital home page Accessed November 6, 2026
- S2NaviMed Capital: Investment Criteria Accessed November 6, 2026
- S3NaviMed Capital: Portfolio Accessed November 6, 2026
- S4NaviMed Capital: News Accessed November 6, 2026
- S5NaviMed Capital: Team Accessed November 6, 2026
- S6Metrix and Versado Communication Establish a Combined Platform (June 16, 2026) Accessed November 6, 2026
- S7Gauge Capital: Lucent Health Announces Next Phase of Growth (April 9, 2024) Accessed November 6, 2026
Compiled by Greymont Advisors from public sources, including the firm’s own website and press releases. Greymont is not affiliated with NaviMed Capital. Figures are as reported on the dates shown and may have changed. Request a correction